Home

Thank you to all our visitors and everyone involved in delivering a fantastic event this year. If you would like to be involved on the organising committee for a future event, please get in touch.

Advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML and digital health are transforming our understanding of disease leading to an explosion of new opportunities in drug discovery.

Join us to hear scientific leaders explore how these advances are being used to identify new drug targets and create opportunities for improved pre-clinical work and clinical trials design.

“Outstanding presenters and presentations. Great balance of strategic direction and practical impact. Thought provoking and insightful, and from a number of different perspectives. Quality of presenters, panel discussions, facilitators universally excellent.”

Exhibitors

Networking

Poster sessions

Talks

Keynote speakers

Professor Sir Munir Pirmohamed

NHS Chair of Pharmacogenetics, University of Liverpool

Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences

Commissioner on Human Medicines (CHM) | UK

Dr. Melanie Lee CBE

CEO, Think 10

Formerly CEO, LifeArc | UK

Full speaker list

Key dates 2024

Supported by

Our sponsors

AstraZeneca has provided a sponsorship grant towards this independent Programme

About

About

IN-PERSON and ONLINE | 29 – 30 April 2024 

Target to Patient conference is returning to Hinxton Hall Conference Centre, Wellcome Genome Campus, Cambridge, UK OR online via our dedicated Target to Patient conference web portal.

Both audiences, face-to-face and virtual, will experience presentations from our esteemed panel of speakers, participate in live Q&A and panel discussion sessions, take advantage of networking opportunities, poster sessions, vendor exhibitions and on-demand materials.

This meeting will focus on ground-breaking advances in genomics for target choice, in vitro technologies, novel modalities, risk mitigation, data analysis, AI/ML, digital health, and how they could radically increase the discovery of disease relevant biological targets and the development of new drugs.

Participants from industry, academia and government interested in challenging the existing approaches to target selection and translation are encouraged to attend, and set the agenda for the next era of drug discovery.

Abstracts for consideration for poster presentations can be submitted during registration. 

Scientific organising committee

Martin Bayliss

GSK, UK

Ian Gilmore

NPL, UK

Mike Hann

GSK, UK

Michael Johnson

Imperial College London, UK

Andrew Leach

EMBL-EBI, UK

Samantha Peel

AstraZeneca, UK

Claire Steppan

Pfizer, USA

Supported by

Our sponsors

AstraZeneca has provided a sponsorship grant towards this independent Programme

Speakers

Keynote speakers

Professor Sir Munir Pirmohamed

NHS Chair of Pharmacogenetics, University of Liverpool

Director of the Wolfson Centre for Personalised Medicine and MRC Centre for Drug Safety Sciences

Commissioner on Human Medicines (CHM) | UK

Dr. Melanie Lee CBE

CEO, Think 10

Formerly CEO, LifeArc | UK

Conference speakers | 29 April

Session 1 – Approaches to target selection 

Dr David Hulcoop 

Director 

Open Targets | UK

Dr Marcus Bantscheff 

Senior Director

GSK Cellzome | Germany

Yuge Ji

Computational Health Center

HelmholtzAI | Germany

Session 2 – Novel tools and approaches in complex in vitro cellular models

Dr Lorna Ewart 

Chief Scientific Officer

Emulate Inc. | UK

Professor Tony NG

Richard Dimbleby Chair of Cancer Research, King’s College London

Vice President and Head of Oncology Translational Research, GSK | UK

Professor Martin Knight 

Centre for Predictive in vitro Models

Queen Mary University of London | UK

Session 3 – Emerging and re-emerging modalities  

Dr Emanuela Cuomo

Senior Director, Early Oncology

AstraZeneca | UK

Dr Matthias Brand

Chief Scientific Officer

Proxygen | Austria

Dr Ian Taylor

Chief Scientific Officer

Arvinas | UK

Conference speakers | 30 April

Session 4 – Risk mitigation strategies  

Dr Jack Scannell

CEO,

Etheros Pharmaceuticals Corp. | UK

Professor Dr Alexander Schuhmacher

Professor for Life Science Management

THI Business School  Ingolstadt | Germany 

Laura Williams

Decision Analyst

GSK, UK

Session 5 – Informatics, computation and AI/ML  

Dr Cynthia Sandor

Emerging Leader

UK DRI

Dr Darren Green

Head of Cheminformatics & Data Science

GSK | UK

Dr Nicola Richmond

Vice President of AI

BenevolentAI | UK

Programme | Posters

Programme

Poster session

For in-person attendees, the poster sessions will be held on Monday 29 and Tuesday 30 April in the event space. For our virtual attendees, posters will be available to view online via the conference portal.

Abstracts should be submitted during registration.

Deadline for poster submissions:     1 April 2024

Notification of poster acceptance: 15 April 2024

Submission information

• Poster submission is open to all in-person attendees.
• Abstracts should be of your work that are relevant to the topics in the meeting, successful abstracts will be notified by the organising committee.
• A digital copy of your poster submission will be requested if your abstract is accepted and used to display on our online conference platform in advance.
• Poster boards will be available on Sunday 28 April from 16:30 ready for you to display your posters.
• Posters can be left up throughout the conference, until Tuesday 30 April at the end of the conference.
• Please note posters must be taken down by 18:00 on the 30 April. 
• For in-person attendees presenting a poster, please note our poster size guidelines: Europe – A0 portrait style, US – 48″ x 36″ portrait style

Registration

Registration

Contact

Contact us

For any questions about the registration process or event logistics, do not hesitate to contact:

Lucie Smith

Event Manager

targettopatient@ebi.ac.uk

Emily Pomeroy

Events and Marketing Officer

targettopatient@ebi.ac.uk

---

Venue information

Venue information

This workshop will be held at: Hinxton Hall Conference Centre, Wellcome Genome Campus, CB10 1RQ.

Set within a one hundred acre estate bordering the River Cam, Hinxton Hall Conference Centre is located on the Wellcome Genome Campus, alongside research institutions that are at the forefront of the genomics revolution.  

+44 (0)1223 495123

Visitor information

Registration is now closed. Access to the conference portal has now been sent to all registered attendees attending in person and online, get in touch with us if you have registered but not received the details.

Registration fees

Early bird in person: £225
Early bird virtual: £225

Standard in person: £275 Standard virtual: £275

Student rate: £110*

Academic rate: £150

Conference dinner: £25

*Limited places available, in person attendance only

Amex payments not accepted

Fees include

The full conference programme: Monday 29 – Tuesday 30 April 2024

Optional welcome dinner and drinks, and early registration on Sunday 28 April (for in person attendees)

Live and recorded presentations

Panel discussions

Live Q&A poster sessions

Access to our vendor exhibition

Networking opportunities

Access to dedicated on-line conference portal and on-demand materials

Important notes

Registration for delegates attending in person closes 18 April 2024

Registration for delegates attending virtually closes 22 April 2024

Discounts are available for students and delegates from academic organisations

Further information

If you require a letter of invitation for a visa application, please contact: targettopatient@ebi.ac.uk

For help with meeting registration, please contact: targettopatient@ebi.ac.uk

Exhibitors

Exhibitors at Target to Patient

T2P2024 will have an exhibitor’s area integrated into the conference, offering CRO and platform providers the opportunity to engage with the participants at this prestigious conference.

We particularly welcome exhibitors relevant to any of the sessions or the strategic aims of the overall conference, which attracts life scientists from academia, the bitotech/pharma industry and policy makers interested in emerging approaches to drug discovery and deployment for the next decade and beyond.  

The exhibitor area is being supported by ELRIG, the leading European not-for-profit organization providing scientific content and exhibition events at life science conferences.

For more, information on exhibitor packages available, please contact Tara Shanks at ELRIG.

Confirmed exhibitors

Supported charity

Supported by

Our sponsors

AstraZeneca has provided a sponsorship grant towards this independent Programme